Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Telomir Pharmaceuticals (NASDAQ:TELO) announces that its Special Advisor, Dr. Michael F. Roizen, will be featured on Health Uncensored with Dr. Drew on Fox Business Network on Sunday, September 29, 2024, at 5:30 PM EST. Dr. Roizen will discuss the science of longevity and the importance of telomeres in the aging process, focusing on Telomir-1, the company's novel small molecule designed to elongate telomere caps.
The segment will explore how Telomir-1 could potentially transform the treatment of age-related conditions and extend healthy human and canine lifespans. Dr. Roizen, a leading wellness and longevity specialist, will explain the critical role of telomeres in aging and how Telomir-1 offers an opportunity to support stem cell health and target aging mechanisms.
Erez Aminov, Chairman and CEO of Telomir, highlighted the company's ongoing research projects aimed at expediting regulatory applications for Telomir-1 in both veterinary and human applications.
Telomir Pharmaceuticals (NASDAQ:TELO) annuncia che il suo Consigliere Speciale, il Dr. Michael F. Roizen, sarà ospite di Health Uncensored with Dr. Drew sulla Fox Business Network domenica 29 settembre 2024, alle 17:30 EST. Il Dr. Roizen discuterà della scienza della longevità e dell'importanza dei telomeri nel processo di invecchiamento, concentrandosi su Telomir-1, la nuova piccola molecola dell'azienda progettata per allungare i cappucci telomerici.
Il segmento esplorerà come Telomir-1 potrebbe potenzialmente trasformare il trattamento delle condizioni legate all'età e prolungare la durata della vita sana degli esseri umani e dei cani. Il Dr. Roizen, un esperto leader nel benessere e nella longevità, spiegherà il ruolo cruciale dei telomeri nell'invecchiamento e come Telomir-1 offra un'opportunità per supportare la salute delle cellule staminali e mirare ai meccanismi dell'invecchiamento.
Erez Aminov, Presidente e CEO di Telomir, ha sottolineato i progetti di ricerca in corso dell'azienda volti ad accelerare le domande regolatorie per Telomir-1 sia nelle applicazioni veterinarie che umane.
Telomir Pharmaceuticals (NASDAQ:TELO) anuncia que su Asesor Especial, el Dr. Michael F. Roizen, aparecerá en Health Uncensored with Dr. Drew en la Fox Business Network el domingo 29 de septiembre de 2024, a las 5:30 PM EST. El Dr. Roizen discutirá la ciencia de la longevidad y la importancia de los telómeros en el proceso de envejecimiento, centrándose en Telomir-1, la novedosa pequeña molécula de la empresa diseñada para alargar los capuchones teloméricos.
El segmento explorará cómo Telomir-1 podría transformar potencialmente el tratamiento de las condiciones relacionadas con la edad y extender la vida útil saludable de los seres humanos y los perros. El Dr. Roizen, un especialista líder en bienestar y longevidad, explicará el papel crítico de los telómeros en el envejecimiento y cómo Telomir-1 ofrece una oportunidad para apoyar la salud de las células madre y atacar los mecanismos del envejecimiento.
Erez Aminov, Presidente y CEO de Telomir, destacó los proyectos de investigación en curso de la empresa destinados a acelerar las aplicaciones regulatorias para Telomir-1 tanto en aplicaciones veterinarias como humanas.
텔로미르 제약회사(TNASDAQ:TELO)는 특별 고문인 마이클 F. 로이젠 박사가 Dr. Drew와 함께하는 건강 무삭제판에 출연할 것이라고 발표했습니다. 방송은 2024년 9월 29일 일요일, 동부 표준시 5시 30분에 FOX 비즈니스 네트워크에서 진행됩니다. 로이젠 박사는 장수 과학과 노화 과정에서 텔로미어의 중요성에 대해 논의하며, 텔로미르-1에 중점을 두고, 이는 텔로미어 캡을 연장하도록 설계된 회사의 새로운 소분자입니다.
이 세그먼트에서는 텔로미르-1이 노화 관련 질환 치료를 어떻게 혁신할 수 있을지, 그리고 건강한 인간과 개의 수명을 어떻게 연장할 수 있을지를 탐구할 것입니다. 웰빙 및 장수 전문인 로이젠 박사는 노화에서 텔로미어의 중요한 역할을 설명하고, 텔로미르-1이 줄기세포 건강을 지원하며 노화 메커니즘을 타겟팅할 수 있는 기회를 제공한다고 말할 것입니다.
텔로미르의 회장 겸 CEO인 에레즈 아미노프는 텔로미르-1에 대한 규제 신청을 가속화하기 위한 회사의 지속적인 연구 프로젝트를 강조했습니다.
Telomir Pharmaceuticals (NASDAQ:TELO) annonce que son conseiller spécial, le Dr. Michael F. Roizen, sera présent dans l'émission Health Uncensored with Dr. Drew sur la Fox Business Network le dimanche 29 septembre 2024, à 17h30 EST. Le Dr. Roizen discutera de la science de la longévité et de l'importance des télomères dans le processus de vieillissement, en se concentrant sur Telomir-1, la nouvelle petite molécule de l'entreprise conçue pour allonger les capuchons de télomères.
Le segment explorera comment Telomir-1 pourrait potentiellement transformer le traitement des affections liées à l'âge et prolonger la durée de vie en bonne santé des humains et des chiens. Le Dr. Roizen, un spécialiste de la santé et de la longévité, expliquera le rôle crucial des télomères dans le vieillissement et comment Telomir-1 offre une opportunité de soutenir la santé des cellules souches et de cibler les mécanismes de vieillissement.
Erez Aminov, président et CEO de Telomir, a souligné les projets de recherche en cours de l'entreprise visant à accélérer les demandes réglementaires pour Telomir-1 dans les applications vétérinaires et humaines.
Telomir Pharmaceuticals (NASDAQ:TELO) gibt bekannt, dass sein Sonderberater, Dr. Michael F. Roizen, in der Sendung Health Uncensored with Dr. Drew im Fox Business Network am Sonntag, den 29. September 2024, um 17:30 Uhr EST zu sehen sein wird. Dr. Roizen wird über die Wissenschaft der Langlebigkeit und die Bedeutung von Telomeren im Alterungsprozess sprechen und sich auf Telomir-1 konzentrieren, das neuartige kleine Molekül des Unternehmens, das entwickelt wurde, um Telomerkappen zu verlängern.
Das Segment wird untersuchen, wie Telomir-1 potenziell die Behandlung altersbedingter Erkrankungen transformieren und die gesunde Lebensdauer von Menschen und Hunden verlängern könnte. Dr. Roizen, ein führender Spezialist für Wellness und Langlebigkeit, wird die entscheidende Rolle von Telomeren beim Altern erläutern und wie Telomir-1 eine Möglichkeit bietet, die Gesundheit der Stammzellen zu unterstützen und Alterungsmechanismen anzugehen.
Erez Aminov, Vorsitzender und CEO von Telomir, hob die laufenden Forschungsprojekte des Unternehmens hervor, die darauf abzielen, die regulatorischen Anträge für Telomir-1 sowohl in der veterinärmedizinischen als auch in der humanmedizinischen Anwendung zu beschleunigen.
- Telomir-1 has potential to transform treatment of age-related conditions
- Company is expediting regulatory applications for both veterinary and human use
- Increased visibility through national TV appearance on Fox Business Network
- Telomir-1 is still in preclinical stage
- No concrete timeline provided for clinical trials or regulatory approvals
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business Network
MIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network.
In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F. Roizen, MD, Emeritus Chief Wellness Officer at Cleveland Clinic, will join Dr. Drew Pinsky to discuss the science of longevity and the importance of telomeres (the protective end caps of chromosomes) on the aging process. The segment will explore how the Company's Telomir-1-a novel small molecule designed to elongate telomere caps-could potentially transform the treatment of age-related conditions and extend healthy human and canine lifespans. Dr. Roizen is a leading wellness and longevity specialist and author of 9 New York Times bestsellers, including 4 #1 bestsellers.
Dr. Roizen will provide insight into the critical importance of Telomir-1 for longevity science, explaining how telomeres play a vital role in the aging process. "The length of our telomeres directly influences how quickly we age and how susceptible we are to age-related diseases," said Dr. Roizen. "A drug like Telomir-1 offers an opportunity to elongate telomeres and support stem cell health, in essence targeting the very mechanisms of aging, with the potential to not only promote longevity but improve the overall quality of life as we age."
Erez Aminov, Chairman and CEO of Telomir, added, "We have launched multiple research projects to expedite the submission of both veterinary and human regulatory applications for Telomir-1, aiming to bring what could be one of the greatest discoveries in longevity science to the forefront. Telomir-1 holds the potential to significantly impact how we approach aging, and with these ongoing studies, we are committed to accelerating the path to clinical trials. We want to thank Dr. Drew for affording us the opportunity to spread the word about this exciting science."
Audiences are encouraged to tune in to Health Uncensored with Dr. Drew on the Fox Business Network this Sunday to get an inside look at Telomir's work and the future of therapies targeting the aging process and age-related conditions.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in longevity science in both humans and animals. The Company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.
Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop, gain regulatory approval for and commercialize Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.
Cautionary Note Regarding Forward-Looking Statements
This press release, the television interview discussed herein and the statements of Telomir's management or advisors contained in or related thereto, contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) anticipated timelines for preclinical and clinical testing of Telomir-1, and (ii) the potential therapeutic benefits of Telomir-1 generally and (iii) the potential lead indications for Telomir-1.
Any forward-looking statements in this press release or in the television interview discussed herein are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723
SOURCE: Telomir Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When will Telomir Pharmaceuticals (TELO) be featured on Health Uncensored with Dr. Drew?
What is Telomir-1 and how does it relate to longevity science?
Who will represent Telomir Pharmaceuticals (TELO) on the TV show?
What are the current development stages of Telomir-1 by Telomir Pharmaceuticals (TELO)?
